Alcon AG vs Invesco Preferred ETF — how do they compare? Alcon AG trades at $73.45 (market cap $35.19B), while Invesco Preferred ETF trades at $10.64. The key difference: Alcon AG pays a 0.49% dividend while Invesco Preferred ETF pays none, and Alcon AG is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| ALC | PGX | |
|---|---|---|
Market Cap | $35.19B | — |
Sector | Health | — |
52-Week High | $90.12 | $11.87 |
52-Week Low | $62.02 | $10.65 |
Enterprise Value | $39.03B | — |
Dividend Yield | 0.49% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
PGX trades at $10.72 with a slight 0.28% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $11 across multiple levels. Recent corporate actions include scheduled dividends for mid-2026, but current financial ratios and income statements lack available data for fundamental assessment.
The outlook remains cautious due to bearish technical signals and limited fundamental visibility. Investment opportunities hinge on future financial disclosures and business developments, while risks include technical downtrend continuation and potential volatility from unresolved financial metrics.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →